These findings confirm that MSCBif stably retains the expression of target genes, is non-immunogenic, and provides a unique advantage in locally targeting DR4/DR5 in resected residual GBM as compared to other engineered stem cell types. The gene discussed is TNFRSF10A; the disease is glioblastoma.